Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma

Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review

(2023) Fabio Efficace et al.   HemaSphere

Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

(2023) Dai Chihara et al.   BLOOD

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

(2023) Jason R. Westin et al.   CLINICAL CANCER RESEARCH

CAR T‐cell therapy in large B cell lymphoma

(2023) Alexander P. Boardman et al.   HEMATOLOGICAL ONCOLOGY

Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma

(2023) Laura K. Hilton et al.   JOURNAL OF CLINICAL ONCOLOGY

ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.

(2023) Jason Westin et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

(2023) Jason R. Westin et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development

(2023) Michael J. Dickinson et al.   Cancer Discovery

The race is on: bispecifics vs CAR T-cells in B-cell lymphoma

(2023) Ashwath Gurumurthi et al.   Blood Advances

Cellular therapy in lymphoma

(2023) Anna Sureda et al.   HEMATOLOGICAL ONCOLOGY

High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions

(2023) Edward R. Scheffer Cliff et al.   American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?

(2022) Jason Westin et al.   BLOOD

Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma

(2022) Max J. Gordon et al.   LEUKEMIA & LYMPHOMA

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

(2022) Sattva S. Neelapu et al.   NATURE MEDICINE

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

(2022) Mahmoud Elsawy et al.   BLOOD

Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma

(2022) Swetha Kambhampati et al.   BLOOD

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

(2022) Mi Kwon et al.   HAEMATOLOGICA

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

(2022) Manali Kamdar et al.   LANCET

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

(2022) Alison Sehgal et al.   LANCET ONCOLOGY

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

(2022) Emmanuel Bachy et al.   NATURE MEDICINE

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

(2022) Jeremy S. Abramson et al.   Blood Advances

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study

(2022) Jeremy S Abramson et al.   BLOOD

Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

(2022) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequencing therapy in relapsed DLBCL

(2022) Christopher R. Flowers et al.   Hematology-American Society of Hematology Education Program

Diffuse Large B-Cell Lymphoma

(2021) Laurie H. Sehn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

(2021) Michael R. Bishop et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

(2021) Frederick L. Locke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

(2020) Sattva S. Neelapu et al.   BLOOD

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

(2019) Nancy L. Bartlett et al.   JOURNAL OF CLINICAL ONCOLOGY

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

(2019) Yucai Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

(2014) Michael Crump et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY